EP3992204A4 - Cell for resisting transplant reaction and method - Google Patents

Cell for resisting transplant reaction and method Download PDF

Info

Publication number
EP3992204A4
EP3992204A4 EP20830547.4A EP20830547A EP3992204A4 EP 3992204 A4 EP3992204 A4 EP 3992204A4 EP 20830547 A EP20830547 A EP 20830547A EP 3992204 A4 EP3992204 A4 EP 3992204A4
Authority
EP
European Patent Office
Prior art keywords
cell
transplant reaction
resisting transplant
resisting
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20830547.4A
Other languages
German (de)
French (fr)
Other versions
EP3992204A1 (en
Inventor
Zonghai Li
Zhaohui Liao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crage Medical Co Ltd
Original Assignee
Crage Medical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crage Medical Co Ltd filed Critical Crage Medical Co Ltd
Publication of EP3992204A1 publication Critical patent/EP3992204A1/en
Publication of EP3992204A4 publication Critical patent/EP3992204A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
EP20830547.4A 2019-06-28 2020-06-29 Cell for resisting transplant reaction and method Pending EP3992204A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910576425 2019-06-28
CN201910809425 2019-08-29
PCT/CN2020/098930 WO2020259707A1 (en) 2019-06-28 2020-06-29 Cell for resisting transplant reaction and method

Publications (2)

Publication Number Publication Date
EP3992204A1 EP3992204A1 (en) 2022-05-04
EP3992204A4 true EP3992204A4 (en) 2023-09-27

Family

ID=74060745

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20830547.4A Pending EP3992204A4 (en) 2019-06-28 2020-06-29 Cell for resisting transplant reaction and method

Country Status (9)

Country Link
US (1) US20220356447A1 (en)
EP (1) EP3992204A4 (en)
KR (1) KR20220028090A (en)
AU (1) AU2020304139A1 (en)
BR (1) BR112021026416A8 (en)
CA (1) CA3144549A1 (en)
IL (1) IL289353A (en)
MX (1) MX2021015620A (en)
WO (1) WO2020259707A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019014986A8 (en) * 2017-01-23 2022-10-18 Carsgen Therapeutics Co Ltd ANTIBODY THAT TARGETS BCMA AND USE THEREOF
CA3107515A1 (en) * 2018-07-24 2020-01-30 Carsgen Therapeutics Co., Ltd. Method for tumor treatment with immune effector cells
WO2023284875A1 (en) * 2021-07-16 2023-01-19 克莱格医学有限公司 Chimeric antigen receptor
WO2023284874A1 (en) * 2021-07-16 2023-01-19 克莱格医学有限公司 Composition and method for tumor immunology

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170016025A1 (en) * 2014-03-11 2017-01-19 Cellectis Method for generating t-cells compatible for allogenic transplantation
CN107828730A (en) * 2017-11-07 2018-03-23 南京北恒生物科技有限公司 Universal CART/TCRT cells and its construction method with antibody drug resistance

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
CA3021455A1 (en) * 2016-04-20 2017-10-26 Fred Hutchinson Cancer Research Center Immunomodulatory il2r fusion proteins and uses thereof
BR112019014986A8 (en) * 2017-01-23 2022-10-18 Carsgen Therapeutics Co Ltd ANTIBODY THAT TARGETS BCMA AND USE THEREOF
CA3058425A1 (en) * 2017-03-28 2018-10-04 The Trustees Of The University Of Pennsylvania Methods to protect transplanted tissue from rejection
CN107746831B (en) * 2017-11-07 2019-04-23 南京北恒生物科技有限公司 Universal CART/TCRT cell and its construction method with chemotherapeutic drug resistance

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170016025A1 (en) * 2014-03-11 2017-01-19 Cellectis Method for generating t-cells compatible for allogenic transplantation
CN107828730A (en) * 2017-11-07 2018-03-23 南京北恒生物科技有限公司 Universal CART/TCRT cells and its construction method with antibody drug resistance

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DENG XINNA ET AL: "Antitumor Activity of NKG2D CAR-T Cells Against Human Colorectal Cancer Cells in Vitro and in Vivo", AMERICAN JOURNAL OF CANCER RESEARCH, vol. 9, no. 5, 15 May 2019 (2019-05-15), US, pages 945 - 958, XP055773925, ISSN: 2156-6976 *
SANBER KHALED ET AL: "Graft- versus -host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells", BRITISH JOURNAL OF HAEMATOLOGY, vol. 195, no. 5, 25 May 2021 (2021-05-25), Hoboken, USA, pages 660 - 668, XP093073886, ISSN: 0007-1048, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1111/bjh.17544> DOI: 10.1111/bjh.17544 *
See also references of WO2020259707A1 *

Also Published As

Publication number Publication date
BR112021026416A2 (en) 2022-02-08
KR20220028090A (en) 2022-03-08
BR112021026416A8 (en) 2022-06-28
CA3144549A1 (en) 2020-12-30
WO2020259707A1 (en) 2020-12-30
AU2020304139A1 (en) 2022-02-24
MX2021015620A (en) 2022-04-18
IL289353A (en) 2022-02-01
EP3992204A1 (en) 2022-05-04
US20220356447A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
EP3992204A4 (en) Cell for resisting transplant reaction and method
EP3874030A4 (en) Compositions and methods for t cell engineering
EP3905277A4 (en) Solid electrolyte composition and production method for solid electrolyte member
EP3966316A4 (en) Modified pluripotent cells
EP3658505A4 (en) Method, cell and electrolyte for dinitrogen conversion
EP3822342A4 (en) Method for producing gamma delta t cells
EP3943586A4 (en) Cell culture system and cell culture method
EP3965459A4 (en) Method and apparatus for activating secondary cell
EP3425412A4 (en) Reaction estimation method for secondary battery and secondary battery comprising battery cell used for same
EP3946439A4 (en) Compositions and methods for preparing t cell compositions and uses thereof
EP3912202A4 (en) Solvent-free electrochemical cells
EP3964560A4 (en) Cell culturing system
EP3639316A4 (en) Stacked prismatic architecture for electrochemical cell
EP3973048A4 (en) Compositions and methods for plant cell culture
EP3438237A4 (en) Cell culture vessel, support jig for cell culture vessel and cell culture method
EP3808833A4 (en) Cell culturing system and cell culturing method
EP4013854A4 (en) Cell culture methods
EP4032852A4 (en) Solid electrolyte and method for producing same
EP3962267A4 (en) Composition and method for cryopreservation of cells
EP3966235A4 (en) Engineered t cells
EP4048293A4 (en) Systems and methods for cell culturing
IL304349A (en) Methods for culturing cells
EP3933022A4 (en) Method for manufacturing culture vessel, and culture vessel
EP3951980A4 (en) Solid electrolyte and method for producing solid electrolyte
EP4042868A4 (en) Composition for freezing cells, method for freezing cells, method for culturing cells, and kit for freezing cells

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220128

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

XX Miscellaneous (additional remarks)

Free format text: A REQUEST FOR RESTORATION OF THE RIGHT OF PRIORITY UNDER RULE 49TER.2 PCT IS PENDING BEFORE THE EPO AS DESIGNATED OFFICE.

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
XX Miscellaneous (additional remarks)

Free format text: A REQUEST FOR RESTORATION OF THE RIGHT OF PRIORITY UNDER RULE 49TER.2 PCT IS PENDING BEFORE THE EPO AS DESIGNATED OFFICE.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40074692

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20230825

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/0783 20100101ALI20230821BHEP

Ipc: C12N 5/10 20060101ALI20230821BHEP

Ipc: C07K 14/74 20060101AFI20230821BHEP